Cambridge Investment Research Advisors Inc. increased its stake in Mylan N.V. (NASDAQ:MYL) by 137.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 36,616 shares of the company’s stock after acquiring an additional 21,218 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Mylan were worth $1,149,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MYL. Meeder Asset Management Inc. grew its holdings in shares of Mylan by 76.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock worth $106,000 after acquiring an additional 1,475 shares during the period. BT Investment Management Ltd bought a new stake in shares of Mylan in the 3rd quarter worth approximately $142,000. Global X Management Co. LLC boosted its position in shares of Mylan by 59.2% in the 2nd quarter. Global X Management Co. LLC now owns 4,801 shares of the company’s stock worth $186,000 after purchasing an additional 1,786 shares in the last quarter. Doliver Capital Advisors LP bought a new stake in shares of Mylan in the 2nd quarter worth approximately $201,000. Finally, Eagle Global Advisors LLC bought a new stake in shares of Mylan in the 2nd quarter worth approximately $205,000. 73.86% of the stock is owned by institutional investors.
Several research firms recently issued reports on MYL. Mizuho reissued a “buy” rating and set a $37.00 price target on shares of Mylan in a report on Tuesday, October 24th. BidaskClub upgraded Mylan from a “hold” rating to a “buy” rating in a research note on Friday, October 27th. Royal Bank Of Canada set a $32.00 price objective on Mylan and gave the stock a “hold” rating in a research note on Friday, October 20th. J P Morgan Chase & Co restated an “overweight” rating and issued a $48.00 price objective (up from $44.00) on shares of Mylan in a research note on Friday, October 6th. Finally, Zacks Investment Research upgraded Mylan from a “strong sell” rating to a “hold” rating and set a $43.00 price target for the company in a research note on Tuesday, October 10th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and thirteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $41.49.
Shares of Mylan N.V. (NASDAQ:MYL) traded up $0.38 during trading hours on Thursday, hitting $37.37. 7,303,709 shares of the company were exchanged, compared to its average volume of 5,956,332. The company has a current ratio of 1.46, a quick ratio of 0.95 and a debt-to-equity ratio of 1.05. The company has a market cap of $20,068.08, a P/E ratio of 7.96, a price-to-earnings-growth ratio of 2.05 and a beta of 1.38. Mylan N.V. has a 1 year low of $29.39 and a 1 year high of $45.87.
Mylan (NASDAQ:MYL) last announced its quarterly earnings data on Monday, November 6th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.20 by ($0.10). The firm had revenue of $2.99 billion during the quarter, compared to the consensus estimate of $3.09 billion. Mylan had a return on equity of 20.63% and a net margin of 7.28%. The firm’s revenue for the quarter was down 2.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.38 EPS. equities research analysts predict that Mylan N.V. will post 4.56 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Cambridge Investment Research Advisors Inc. Has $1.15 Million Holdings in Mylan N.V. (MYL)” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2017/12/07/cambridge-investment-research-advisors-inc-has-1-15-million-stake-in-mylan-n-v-myl.html.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.